Primary hyperaldosteronism
Conditions
Interventions
Index test:[18F]AlF-NOTA-Pentixafor PET/CT imaging
Sponsors
Peking University Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1?The patient voluntarily participated in this study and signed an informed consent form. 2?Age>=18 years old and<=years old (based on the date of signing the informed consent form), gender is not limited. 3?The main inclusion criteria for patients are those with high suspicion of PA based on clinical manifestations and other imaging examinations. 4?The patient obtained pathological results within 10 weeks after receiving [18F] AlF NOTA Pentixafor PET/CT imaging. 5?Expected survival time exceeds 12 weeks. 6?Blood routine and liver and kidney function meet the following criteria: Blood routine: WBC = 4.0 × 10^9L or neutrophil = 1.5 × 10^9L, PLT = 100 × 10^9/L, Hb = 90g/L; PT or APTT = 1.5ULN; Liver and kidney function: T-Bil = 1.5 × ULT (upper limit of normal), ALT/AST = 2.5ULN or = 5 × ULT (in patients with liver metastasis), ALP = 2.5ULN (if there is bone metastasis or liver metastasis, ALP = 4.5ULN); BUN = 1.5 × ULT, SCr = 1.5 × ULT). 7?Willing and able to comply with diagnostic plans, clinical laboratory tests, and other research procedures.
Exclusion criteria
Exclusion criteria: 1?Emergency treatment for critically ill patients; Severe respiratory failure or airway obstruction caused by respiratory system diseases; 2?There are contraindications for PET/CT scanning. Including but not limited to uncontrolled blood glucose elevation; Women who are preparing for pregnancy, pregnant or breastfeeding; Individuals who are known to be allergic to radioactive drugs or their excipients (including those with a history of severe allergies or allergic reactions, especially those who are allergic to the tested drug). 3?Patients who cannot tolerate or fail to complete preliminary clinical examinations; 4?Previously used radioactive isotopes with an interval of less than 10 physical half lives from the time of administration in this study. 5?According to the researcher's judgment, it is not suitable to participate in this study. 6?Combine patients with the second type of primary tumor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sensitivity;Accuracy;Specificity; | — |
Countries
China
Contacts
Public ContactHaibo Chen
Peking University Shenzhen Hospital
Outcome results
None listed